Table 1. Patient demographics and... | American Society of Hematology

Table 1.

Patient demographics and baseline clinical characteristics

Characteristic	n	%
Total number of patients	27
Median age (range), y	69 (57-84)
Sex
Male	21	77.8
Female	6	22.2
ECOG performance status
0	23	85.2
1	4	14.8
Diagnosis
CLL	23*	85.2
SLL	4	14.8
Rai stage at therapy initiation
1	3	11.1
2	5	18.5
3	4	14.8
4	15	55.6
Cytogenetics (Döhner hierarchy)
17p deletion	3	11.1
11q deletion	3	11.1
Trisomy 12	7	25.9
13q deletion	8	29.6
Normal	6	22.2
IGHV status
Mutated >2%	14	51.8
Unmutated	13	48.1
ZAP-70 status
Negative	9	33.3
Positive	14	51.9
Not recorded	4	14.8
High-risk features
17p deletion only	1	3.7
TP53 mutation only	2	7.4
Both TP53 mutation and 17p deletion	2	7.4
NOTCH1 mutation	3	11.1
Bulky adenopathy†	8	29.6
Median β₂ microglobulin (range), mg/L	5.2 (2.4-14.6)

Characteristic	n	%
Total number of patients	27
Median age (range), y	69 (57-84)
Sex
Male	21	77.8
Female	6	22.2
ECOG performance status
0	23	85.2
1	4	14.8
Diagnosis
CLL	23*	85.2
SLL	4	14.8
Rai stage at therapy initiation
1	3	11.1
2	5	18.5
3	4	14.8
4	15	55.6
Cytogenetics (Döhner hierarchy)
17p deletion	3	11.1
11q deletion	3	11.1
Trisomy 12	7	25.9
13q deletion	8	29.6
Normal	6	22.2
IGHV status
Mutated >2%	14	51.8
Unmutated	13	48.1
ZAP-70 status
Negative	9	33.3
Positive	14	51.9
Not recorded	4	14.8
High-risk features
17p deletion only	1	3.7
TP53 mutation only	2	7.4
Both TP53 mutation and 17p deletion	2	7.4
NOTCH1 mutation	3	11.1
Bulky adenopathy†	8	29.6
Median β₂ microglobulin (range), mg/L	5.2 (2.4-14.6)

SLL, small lymphocytic lymphoma.

One patient’s diagnosis was later reclassified to lymphoplasmacytic lymphoma.

Bulky indicates the presence of ≥1 node with a diameter ≥5 cm.